treating
Disease Networks
Developing Therapies that Target Cell Networks and Tumor Microenvironments Instead of “Single Target” Drugs.
Oncology
The body of international basic cancer research on synthetic triterpenoids discovered by TTX founder Dr. Michael B. Sporn is voluminous and promising. TTX drugs were designed originally to treat cancers and are based on the understanding that inflammation and oxidative stress are unique and important drivers of carcinogenesis. In ongoing research TTX’s lead compound 2P-Im has been shown to be effective in animals as a treatment for Multiple Myeloma and Glioblastoma. TTX plans to utilize its developing pipeline for the treatment of Multiple Myeloma, Glioblastoma, Breast, Ovarian and Lung cancers.
Other Chronic Diseases
Inflammation and oxidative stress are not confined to cancers. They play a key role in the causation of many other chronic diseases throughout the body. Because of their ability to achieve high concentrations in many organs, including penetration of the blood-brain barrier, TTX drugs offer promising treatment for major neurodegenerative diseases such as Parkinson’s, Alzheimer’s, multiple sclerosis, and amyotrophic lateral sclerosis (ALS).